Olaparib for the treatment of ovarian cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA-Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of brca1 and brca2 penetrance. J Clin Oncol 2007;25:1329-33
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. Brca mutation frequency and patterns of treatment response in brca mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012;30:2654-63
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):24-32
   Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, et al. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10:211-24
   PubMed Web of Science ®Google Scholar
• Friedlander ML, Stockler MR, Butow P, et al. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol 2013;31:2362
   PubMed Web of Science ®Google Scholar
• Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. CR Rev Oncol-Hem 2007;64:129-38
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013;19:961-8
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47(Suppl 3):S116-30
   PubMedGoogle Scholar
• Ratner ES, Sartorelli AC, Lin ZP. Poly (adp-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012;24:564-71
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. Parp inhibition: parp1 and beyond. Nat Rev Cancer 2010;10:293-301
   PubMed Web of Science ®Google Scholar
• Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001;307:1235-45
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99
   PubMed Web of Science ®Google Scholar
• Pettitt SJ, Rehman FL, Bajrami I, et al. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS ONE 2013;8:e61520
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
   PubMed Web of Science ®Google Scholar
• Marchetti C, Imperiale L, Gasparri ML, et al. Olaparib, parp1 inhibitor in ovarian cancer. Expert Opin Investig Drugs 2012;21:1575-84
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2h-phthalazin- 1-one: a novel bioavailable inhibitor of poly(adp-ribose) polymerase-1. J Med Chem 2008;51:6581-91
   PubMed Web of Science ®Google Scholar
• Investigator brochure for olaparib, [edition no.10] dated 14th November 2013
   Google Scholar
• Yamamoto N, Nokihara H, Yamada Y, et al. A phase 1, dose-finding and pharmacokinetic study of olaparib (azd2281) in Japanese patients with advanced solid tumors. Cancer Sci 2012;103:504-9
   PubMed Web of Science ®Google Scholar
• Molife LR, Forster MD, Krebs M, et al. A phase 1 study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (azd2281), in patients with advanced solid tumors. ASCO Meeting Abstracts 2010;28:2599
   Google Scholar
• Gupta A, Moreno V, Dean EJ, et al. Phase 1 study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: dose-escalation phase. ASCO Meeting Abstracts 2012;30:3051
   Google Scholar
• Molife LR, Mateo J, McGoldrick T, et al. Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. ASCO Meeting Abstracts 2012;30:3048
   Google Scholar
• Mateo J, Friedlander M, Sessa C, Leunen K, et al. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation [abstract 801]. The European Cancer Congress; 2013
   Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. OncoTargets Ther 2013;6:1197-206
   Web of Science ®Google Scholar
• Fong PC, Yap TA, Boss DS, et al. Poly(adp)-ribose polymerase inhibition: frequent durable responses in brca carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-19
   PubMed Web of Science ®Google Scholar
• Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(adp-ribose) polymerase (PARP) inhibitor, olaparib (azd2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase 1 study. Invest New Drug 2012;30:1493-500
   PubMed Web of Science ®Google Scholar
• Khan OA, Gore M, Lorigan P, et al. A phase 1 study of the safety and tolerability of olaparib (azd2281, ku0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011;104:750-5
   PubMed Web of Science ®Google Scholar
• Dent RA, Lindeman GJ, Clemons M, et al. Phase 1 trial of the oral parp inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88
   PubMed Web of Science ®Google Scholar
• Lee J, Annunziata CM, Minasian LM, et al. Phase 1 study of the parp inhibitor olaparib (o) in combination with carboplatin (c) in brca1/2 mutation carriers with breast (br) or ovarian (ov) cancer (ca). ASCO Meeting Abstracts 2011;29:2520
   Google Scholar
• Rajan A, Carter CA, Kelly RJ, et al. A phase 1 combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:2344-51
   PubMed Web of Science ®Google Scholar
• van der Noll R, Ang JE, Jager A, et al. Phase 1 study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. ASCO Meeting Abstracts 2013;31:2579
   Google Scholar
• Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-60
   PubMed Web of Science ®Google Scholar
• Dean E, Middleton MR, Pwint T, et al. Phase 1 study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012;106:468-74
   PubMed Web of Science ®Google Scholar
• Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(adp-ribose) polymerase inhibitor olaparib (azd2281) in combination with the anti-angiogenic cediranib (azd2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013;49:2972-8
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with brca1 or brca2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase 2, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (adp-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with brca1 or brca2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372-9
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase 3 study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22
   PubMed Web of Science ®Google Scholar
• Adams SF, Marsh EB, Elmasri W, et al. A high response rate to liposomal doxorubicin is seen among women with brca mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 2011;123:486-91
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (soc) and a brca mutation (brcam). ASCO Meeting Abstracts 2013;31:5505
   Google Scholar
• Oza AM, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin (p/c) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (psr soc): a randomized, open-label phase 2 study. ASCO Meeting Abstracts 2012;30:5001
   Google Scholar
• Oza AM, Cibula D, Oaknin Benzaquen A, et al. Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses [abstract 3002]. The European Cancer Congress; 2013
   Google Scholar
• Olaparib enters phase 3 clinical testing. Cancer Discov 2013;3:1210
   Google Scholar
• Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25:32-40
   PubMed Web of Science ®Google Scholar
• Secord AA, Barnett JC, Ledermann JA, et al. Cost-effectiveness of brca1 and brca2 mutation testing to target parp inhibitor use in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer 2013;23:846-52
   PubMed Web of Science ®Google Scholar
• George J, Alsop K, Etemadmoghadam D, et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 2013;19:3474-84
   Google Scholar
• Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-65
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A. Hallmarks of 'brcaness' in sporadic cancers. Nat Rev Cancer 2004;4:814-19
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol 2011;22:1127-32
   PubMed Web of Science ®Google Scholar
• Ang JE, Gourley C, Powell CB, et al. Efficacy of chemotherapy in brca1/2 mutation carrier ovarian cancer in the setting of parp inhibitor resistance: a multi-institutional study. Clin Cancer Res 2013;19:5485-93
   PubMed Web of Science ®Google Scholar
• Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in brca2 associated with clinical resistance to a parp inhibitor. J Pathol 2013;229:422-9
   PubMed Web of Science ®Google Scholar
• Aly A, Ganesan S. BRCA1, PARP, and 53bp1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74
   PubMed Web of Science ®Google Scholar
• Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Plummer ER, Elattar A, et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res 2012;72:5675-82
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-8
   PubMed Web of Science ®Google Scholar
• Montoni A, Robu M, Pouliot E, et al. Resistance to parp-inhibitors in cancer therapy. Front Pharmacol 2013;4:18
   PubMed Web of Science ®Google Scholar
• Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer I 2009;101:1642-9
   PubMed Web of Science ®Google Scholar